Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study
-
Published:2023-12-07
Issue:2
Volume:34
Page:179-187
-
ISSN:1048-891X
-
Container-title:International Journal of Gynecologic Cancer
-
language:en
-
Short-container-title:Int J Gynecol Cancer
Author:
Cucinella GiuseppeORCID, Schivardi Gabriella, Zhou Xun Clare, AlHilli Mariam, Wallace Sumer, Wohlmuth Christoph, Baiocchi GlaucoORCID, Tokgozoglu Nedim, Raspagliesi Francesco, Buda AlessandroORCID, Zanagnolo Vanna, Zapardiel IgnacioORCID, Jagasia Nisha, Giuntoli RobertORCID, Glickman Ariel, Peiretti Michele, Lanner Maximilian, Chacon EnriqueORCID, Di Guilmi Julian, Pereira Augusto, Laas-Faron Enora, Fishman Ami, Nitschmann Caroline C, Kurnit KatherineORCID, Moriarty Kristen, Joehlin-Price Amy, Lees Brittany, Covens Allan, De Brot Louise, Taskiran CagatayORCID, Bogani Giorgio, Landoni Fabio, Grassi TommasoORCID, Paniga Cristiana, Multinu FrancescoORCID, De Vitis Luigi AntonioORCID, Hernández Alicia, Mastroyannis Spyridon, Ghoniem Khaled, Chiantera Vito, Shahi Maryam, Fought Angela J, McGree Michaela, Mariani AndreaORCID, Glaser GretchenORCID
Abstract
ObjectiveThe prognostic significance of isolated tumor cells (≤0.2 mm) in sentinel lymph nodes (SLNs) of endometrial cancer patients is still unclear. Our aim was to assess the prognostic value of isolated tumor cells in patients with low risk endometrial cancer who underwent SLN biopsy and did not receive adjuvant therapy. Outcomes were compared with node negative patients.MethodsPatients with SLNs–isolated tumor cells between 2013 and 2019 were identified from 15 centers worldwide, while SLN negative patients were identified from Mayo Clinic, Rochester, between 2013 and 2018. Only low risk patients (stage IA, endometrioid histology, grade 1 or 2) who did not receive any adjuvant therapy were included. Primary outcomes were recurrence free, non-vaginal recurrence free, and overall survival, evaluated with Kaplan–Meier methods.Results494 patients (42 isolated tumor cells and 452 node negative) were included. There were 21 (4.3%) recurrences (5 SLNs–isolated tumor cells, 16 node negative); recurrence was vaginal in six patients (1 isolated tumor cells, 5 node negative), and non-vaginal in 15 (4 isolated tumor cells, 11 node negative). Median follow-up among those without recurrence was 2.3 years (interquartile range (IQR) 1.1–3.0) and 2.6 years (IQR 0.6–4.2) in the SLN–isolated tumor cell and node negative patients, respectively. The presence of SLNs-isolated tumor cells, lymphovascular space invasion, and International Federation of Obstetrics and Gynecology (FIGO) grade 2 were significant risk factors for recurrence on univariate analysis. SLN–isolated tumor cell patients had worse recurrence free survival (p<0.01) and non-vaginal recurrence free survival (p<0.01) compared with node negative patients. Similar results were observed in the subgroup of patients without lymphovascular space invasion (n=480). There was no difference in overall survival between the two cohorts in the full sample and the subset excluding patients with lymphovascular space invasion.ConclusionsPatients with SLNs–isolated tumor cells and low risk profile, without adjuvant therapy, had a significantly worse recurrence free survival compared with node negative patients with similar risk factors, after adjusting for grade and excluding patients with lymphovascular space invasion. However, the presence of SLNs–isolated tumor cells was not associated with worse overall survival.
Subject
Obstetrics and Gynecology,Oncology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|